$HYFT

MindWalk Holdings Corp.

MindWalk is a Bio-Native AI company that combines artificial intelligence, biological data analysis and wet-lab capabilities to support therapeutic discovery for life sciences partners. Its platform is built around patented HYFT® technology, which organizes biological patterns and relationships, and LensAI™, a reasoning and application layer for biologics discovery. ReefIQ™ connects client discovery data to AI workflows, while services include expert-led analytics projects, software subscriptions and API integrations. MindWalk also offers antibody discovery and development capabilities and maintains internal therapeutic and vaccine programs, including assets available for partnerships or licensing. MindWalk makes money through fee-for-service work, LensAI subscriptions and API-based integrations, as well as partnerships and potential licensing of internally developed assets. Its executive headquarters are in Austin, Texas.

AlphAI earnings readFiscal First Quarter 2027 · SEP 14MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027Verdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
0

No SEC Form 4 filings for $HYFT in the last 30 days.

See all $HYFT insider activity →

MindWalk secures multi-year AI deal with Teva Australia

MindWalk (NASDAQ:HYFT) signed a multi-year AI deal with Teva Australia to use its ReefIQ platform for antibody discovery, accelerating design optimization. The agreement is a recurring-revenue relationship, not fee-for-service. Financial terms were not disclosed. MindWalk is in talks with other life sciences firms for similar deployments.

MindWalk chief business officer Thomas Lynch departs

MindWalk Holdings Corp. (HYFT) announced the departure of Chief Business Officer Thomas Lynch, effective October 16. The company stated its commercial priorities remain unchanged, focusing on platform deployments and pharmaceutical engagements. No reason for the departure or a replacement was disclosed. MindWalk develops AI infrastructure for life sciences applications.

HYFT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HYFT (MindWalk Holdings Corp.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent HYFT coverage spans technology, financial news and earnings.

What's driving HYFT

AlphAI scores every news story that mentions HYFT with an AI model for sentiment and relevance, and aggregates insider trades from MindWalk Holdings Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HYFT

Score

MindWalk secures multi-year AI deal with Teva Australia

MindWalk (NASDAQ:HYFT) signed a multi-year AI deal with Teva Australia to use its ReefIQ platform for antibody discovery, accelerating design optimization. The agreement is a recurring-revenue relationship, not fee-for-service. Financial terms were not disclosed. MindWalk is in talks with other life sciences firms for similar deployments.

MindWalk chief business officer Thomas Lynch departs

MindWalk Holdings Corp. (HYFT) announced the departure of Chief Business Officer Thomas Lynch, effective October 16. The company stated its commercial priorities remain unchanged, focusing on platform deployments and pharmaceutical engagements. No reason for the departure or a replacement was disclosed. MindWalk develops AI infrastructure for life sciences applications.

MindWalk's life sciences AI remains in recurring customer deployments as its business chief exits.

MindWalk Holdings Corp. (NASDAQ: HYFT) reports that its AI technology, LensAI™, remains in contracted, recurring deployments with life sciences customers. The company's Chief Business Officer has exited, but commercial priorities remain unchanged. MindWalk focuses on delivering existing platform deployments and advancing pharma engagements. The company's HYFT® Technology powers its biological data substrate, ReefIQ™, and LensAI™.

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

The global AI in drug discovery market is projected to grow significantly, with estimates ranging from $160.49B by 2035 (Towards Healthcare) to $13.8B by 2033 (Grand View Research). MindWalk Holdings Corp. (HYFT) appointed Kim Remizowski to its board, emphasizing governance as the company shifts to deploying AI infrastructure in life sciences. HYFT's technology, HYFT®, powers ReefIQ™ and LensAI™ for biological context and reasoning.

MindWalk Holdings Corp. (NASDAQ: HYFT) announced results from a production deployment of the OpenFold3 model with AMD…

MindWalk Holdings Corp. (NASDAQ: HYFT) announced results from a production deployment of the OpenFold3 model with AMD and Vultr, achieving 5x faster antibody-antigen inference. The deployment expands compute capacity for ReefIQ, MindWalk's biological context layer, and validates AIM for OpenFold3 in a production setting. The company aims to reduce costs and onboarding time for enterprise partners.

StoneX reiterates Speculative Buy on MindWalk stock at $3 target

StoneX reiterated a Speculative Buy rating and $3.00 price target for MindWalk Holdings (HYFT). The company reported Q1 2027 revenue of CAD$3.8M, up 21% YoY, but net loss widened to $6.1M. Analysts predict profitability for fiscal 2027. MindWalk launched ReefIQ and secured a $30M credit facility. H.C. Wainwright also reiterated a Buy rating with a $5.00 target.

Related tickers